Form 4: Calumet Inc. Director Sells Shares Under 10b5-1 Plan

Calumet Inc. Director Daniel J. Sajkowski reported the sale of 4,240 shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Director Daniel J. Sajkowski sold 4,240 shares of Calumet, Inc. common stock.
• The transactions occurred on July 1, 2026.
• These sales were executed as part of a Rule 10b5-1 trading plan established on November 18, 2025.
• The weighted average sale price was $36.16 per share, with individual sales ranging from $35.72 to $36.33.
• Following these transactions, Sajkowski beneficially owns 77,718 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While insider selling can be a negative signal, the execution via a 10b5-1 plan indicates a pre-arranged strategy, reducing immediate concerns about adverse non-public information.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, indicating pre-planned and potentially non-insider trading related activity.
• The director continues to hold a significant number of shares (77,718) after the sale.

Negatives

• A director has sold a portion of their holdings, which could be perceived negatively by the market, although it was pre-planned.
• The sale occurred at a price significantly higher than the price on the date the 10b5-1 plan was adopted ($19.08).

Risks

• Potential for negative market perception due to insider selling, even if executed under a 10b5-1 plan.
• The company's stock price may be subject to volatility if further insider selling occurs.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which solely reports a change in beneficial ownership.

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
• The closing price of one share of Calumet, Inc. common stock, as reported on the Nasdaq Global Select Market, on the date the Rule 10b5-1 trading plan was adopted by the reporting person was $19.08 per share.
• The reporting person undertakes to provide to Calumet, Inc., any security holder of Calumet, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures of insider transactions. While director sales can sometimes signal a lack of confidence, the explicit mention of a Rule 10b5-1 plan suggests a pre-determined selling strategy, mitigating concerns about immediate non-public information.

Stakeholder Impact

• Shareholders: May perceive insider selling as a negative signal, although the 10b5-1 plan mitigates this concern. The continued significant ownership by the director may provide some reassurance.
• Management: The transaction is a standard disclosure for management and directors.
• Employees: No direct impact is indicated in this filing.

Next Steps

• Continue to monitor future Form 4 filings for any additional insider transactions.
• Observe the company's stock performance and any subsequent disclosures for further insights.

Key Dates

Recommendation

The filing reports a routine transaction by a director under a pre-established 10b5-1 plan. While insider selling can be a concern, the structured nature of the sale suggests it's not based on new adverse information. The director retains a substantial number of shares. Therefore, a 'hold' recommendation is appropriate, pending further company performance and strategic updates.

Keywords

Calumet Inc., CLMT, Form 4, Insider Trading, Stock Sale, 10b5-1 Plan, Director Transaction, Beneficial Ownership